Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00479856 · ClinicalTrials.gov registry record · Phase 2
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00479856 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 9 participants.
The verdict
NCT00479856, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
- DRUG Lapatinib
- DRUG nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00479856
The ClinicalTrials.gov registry entry for NCT00479856 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT00479856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00479856 about?
NCT00479856 is a clinical study titled "Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer". This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in t...
What is the current status of trial NCT00479856?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2007-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00479856?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG), Lapatinib (DRUG), nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00479856?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.